Logo
Login

Company Executives

$ Management Team

Mr. Mark Schiller

Chief Legal Officer

Age 45
Compensation $868.4K USD
Sex Male

Mr. Graham Cooper

Independent Chairman of the Board

Age 55
Compensation $114.4K USD
Sex Male

Dr. Christopher Kirk

Chief Executive Officer

Director

Age 53
Compensation $927.3K USD
Sex Male

Mr. Marc Belsky

Chief Financial Officer

Secretary

Age 69
Compensation $915.0K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 25, 2025
Directors
8
serving now
Independent
0 of 2
stated in the proxy; 6 not stated
Average tenure
7.5 years
from year joined
CEO also chairs the board
No
Graham Cooper
Director Age On board Independent Committees Other public boards 2024 pay Source
Elizabeth Garner
57 2019
6 years
 Not stated
Audit Committee
None stated $81,875
Michael Kauffman
61 2016
9 years
 Not stated
Compensation Committee · Chair
Verastem Inc. Not stated
Courtney Wallace
41 2021
4 years
 Not stated
Compensation Committee Nominating and Corporate Governance Committee
None stated $73,375
Franklin Berger
75 2016
9 years
 Not stated
Audit Committee
ESSA Pharma, Inc., Atea Pharmaceuticals, Inc. $79,875
Graham Cooper
Board chair
 55 2017
8 years
 Not stated
Compensation Committee
Beam Therapeutics, Inc. $114,375
John Fowler
53 2015
10 years
 Not independent None stated None stated $57,037
Christopher Kirk
CEO
 53 2015
10 years
 Not independent None stated None stated Paid as CEO
Micki Klearman
70 2021
4 years
 Not stated
Nominating and Corporate Governance Committee
None stated $78,375

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

1 disclosed in the proxy filed Apr 25, 2025
Franklin Berger
holder of our common stock, party to the investors’ rights agreement
Amount not stated
since January 1, 2023

Registration rights under an amended and restated investors’ rights agreement dated June 26, 2017, which terminated on the fifth anniversary of the IPO completed in June 2023.

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans